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Cardiovascular diseases are the main cause of a morbidity and
mortality in Brazil. They have a significant impact on the Health
Ministry budget, especially concerning their high complexity. Due
to the growing demand for funds, the Secretaria de Atenção à
Saúde do Ministério da Saúde (Healthcare Secretariat of Health
Ministry) prepared the Política Nacional de Atenção Cardiovascular
de Alta Complexidade (National Policy of High Complexity Cardio-
vascular Care).
In 2002, 1,216,394 admissions due to circulatory system
diseases were recorded, representing 10.3% from total hospitali-
zations in Sistema Único de Saúde – Unified Healthcare System
- (SUS). Financially, clinical and surgical cardiology admissions
amounted to 17%, a rate higher than all other specialties1.
Amidst the circulatory diseases, heart failure was responsible
for 30.6% of admissions and the diagnosis of “other heart ischemic
diseases”, 10.6%. The financial impact for the Healthcare System
is greater than the quantified one. SUS values regarded as expenses
do not correspond to the real cost with cardiovascular disease
treatment. A recent study on heart failure cost showed the diffe-
rence between values refunded by SUS to hospitals and the real
cost for hospitalization due to that disease2.
The indirect cost represented by unproductiveness,
absenteeism and early death due to cardiovascular diseases is
another economic component. A Brazilian university hospital study
showed that 28.5% of heart failure treatment patients had early
retirement due to the syndrome2.
The high prevalence of chronic ischemic cardiopathy accounts
for the extraordinary use of funds in treatment and rehabilitation.
In 2003, SUS financed 30,666 coronary angioplasties with stent
implantation and 19,909 myocardial revascularization surgeries,
representing a total of approximately R$ 281 million.
The integration of Bare Metal Stent (BMS) to SUS, in 1999,
has produced a significant change in the intervention treatment
of ischemic cardiopathy patients. Myocardial revascularization was
the main type of intervention treatment until 1999. Three years
later, the number of coronary angioplasties increased in more
than 100%. In the same period, there was a significant reduction
in myocardial revascularization surgeries. Conventional stent (BMS)
treatment benefits were important, but with limitations in some
subgroups, especially within the little caliper and greater extension
vessel diabetic patients, in which intra-stent restenosis is
considerable in the first six post-procedure months.
Despite the increase of treatment initial cost, Drug Eluting
Stent (DES) development, non-available at SUS, provided signifi-
cantly lower intra-stent restenosis rates in this subgroup of pa-
tients3,4. Matching budget restriction with the need for assessing
and including new cardiovascular technologies is an impasse faced
by SUS.
Such contradictory scenario has been raising interest among
academicians in the search for new solutions, as we need new
areas of knowledge to help us make decisions in a fund scarce
environment.
Healthcare technology incorporation assessment is an inter-
disciplinary knowledge area to help that selection process. It must
take into consideration the functioning and/or impact of healthcare
products and services, programs or policies on healthcare service
promotion, maintenance and production.
Assessment of a technology to be incorporated by healthcare
system, either public or private, is characterized by a systematic,
critical and thorough review on the available literature. Aspects
as intervention effectiveness, its economic analysis and potential
impact on healthcare system, which means, its contribution to
health promotion, maintenance or rehabilitation, must be taken
into consideration. Ethic aspects and rightness matters must be
regarded in assessment the process.
As a result of the fast technological development, especially
in cardiovascular sector, such assessment process becomes
indispensable, not only for identifying valuable interventions for
the healthcare system, but also for the need of a selecting process
among alternatives which beyond doubt add value to the healthcare
system.
The Centro Paulista de Economia da Saúde – Healthcare
Economics Center of São Paulo (CPES) of Escola Paulista de Me-
dicina (UNIFESP) has been preparing an estimate of the impact
on SUS budget with the use of pharmacological stent, with data
from 2003.
Impact model premises on budget are: conversion from con-
ventional to pharmacological stent, number of stents/patient/pro-
cedure; % of re-interventions through conventional stent restenosis;
% of re-interventions through pharmacological stent restenosis;
stent prices, SUS-paid HAA (Hospital Admission Authorization)
values to hospitals for angioplasty and myocardial revascularization
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surgery; post-procedure Clopidogrel price. Such model has variable
premises according to hypothetical population access percentage
to and purchase price of pharmacological stent, and percentage
of avoided re-intervention in the following 12 months. Those
variations explain possible circumstances from 12.8% to 24.4%
(R$ 24,272,308.00 to R$ 44,458,162.00) of price increase in
the first 12 post-procedure months for SUS.
Healthcare technology assessment agencies as NICE5 and
AETMIS6 have been helping healthcare system sponsors in the
United Kingdom and the province of Quebec, in Canada, to in-
corporate pharmachological stent in cardiological practice.
Dispute on new technology inclusion in SUS is an opportunity
for Sociedade Brasileira de Cardiologia (Brazilian Cardiology As-
sociation) to promote method development to assist cardiovascular
healthcare policy formulators in the selection process among
available alternatives, by quantifying benefits for each cost unit
and estimating the advantages of incorporating new diagnoses
and therapies for the general public.
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